For pharmaceutical and biotechnology companies, it is important to identify as many polymorphic forms of a small molecule therapeutic as possible, to mitigate threats from competitors and to create opportunities to optimise product performance.
Recent advances in Crystec’s modified supercritical antisolvent technology give us high confidence in finding novel solid-state forms. In addition to discovering polymorphs that can be generated using conventional crystallisation, we can also find stable high-pressure polymorphs that can only be made using supercritical techniques. As well as pure forms, we are comfortable screening salts, solvates and hydrates.
A typical solid-state screen takes 6 weeks. We are happy to take a risk-sharing approach with our clients, linked to successfully finding a new solid-state form.
For further information, please contact Zeesharn Farook zeesharn.farook@crystecpharma.com.
